Evidence map›Paper›PMID 25667267›Full record

ArticleInfection and immunity2015

Antibodies against hemolysin and cytotoxic necrotizing factor type 1 (CNF1) reduce bladder inflammation in a mouse model of urinary tract infection with toxigenic uropathogenic Escherichia coli.

Mark A Smith, Rebecca A Weingarten, Lisa M Russo, Christy L Ventura, Alison D O'Brien

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Comparative Pathogenomics ofInfection and immunity · 2021
    Article
  7. EnteroaggregativePeerJ · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mark A SmithDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Rebecca A WeingartenDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Lisa M RussoDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Christy L VenturaDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Alison D O'BrienDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA alison.obrien@usuhs.edu.
Uniformed Services University of the Health Sciences · US

Funding

RHO MODIFYING CYTOTOXIC NECROTIZING FACTOR OF E COLIR01AI038281 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI O'BRIEN, ALISON DAVIS · 1995 to 2013
$3.3M
NIAID NIH HHS AI038281NIAID NIH HHS R01 AI038281
6 · The paper itself

Abstract

Uropathogenic Escherichia coli (UPEC) is the leading cause of cystitis. Cytotoxic necrotizing factor 1 (CNF1) and hemolysin (Hly) are toxins made by approximately 50% of UPEC isolates. CNF1 and Hly contribute to the robust inflammatory response in the bladders of mice challenged with UPEC strain CP9. We hypothesized that antibodies against CNF1 and/or Hly would reduce cystitis caused by CP9. To test this theory, we immunized female C3H/HeOuJ mice subcutaneously with a genetically derived Hly toxoid or genetically derived CNF1 toxoid plus sublethal doses of CNF1. We collected serum and observed increasing titers of specific and neutralizing antibodies against Hly or CNF1 over time. We challenged the mice intraurethrally with CP9 and euthanized them 24 h later. We observed 10-fold lower bacterial titers in the urine of Hly-immunized mice than in that of sham-immunized mice but no difference in kidney bacterial titers. Immunized mice also exhibited significantly less cystitis than sham-immunized mice. In CNF1-vaccinated mice, we detected neither a difference in urine or kidney bacterial titers nor a reduction in the severity of cystitis versus that of sham-immunized mice. We then passively administered an anti-CNF1 monoclonal antibody intraperitoneally to female C3H/HeOuJ mice prior to intraurethral challenge with CP9. Upon challenge, we noted no difference in colonization of the urine or kidney; however, cystitis was reduced significantly in mice treated with the anti-CNF1 antibody versus that in the bladders of mice given an isotype control antibody. Taken together, our data demonstrate that antibodies against CNF1 or Hly reduce the bladder pathology caused by UPEC.

Indexed as

AnimalsAntibodies, MonoclonalBacterial ToxinsCystitisDisease Models, AnimalEscherichia coli InfectionsEscherichia coli ProteinsFemaleHemolysin ProteinsImmune SeraImmunization, PassiveMiceMice, Inbred C3HUrinary BladderUrinary Tract InfectionsUrineAntibodies, MonoclonalBacterial Toxinscytotoxic necrotizing factor type 1Escherichia coli ProteinsHemolysin ProteinsImmune Sera

Identifiers

PMID25667267
PMCPMC4363410
OpenAlexW2144934292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.